News Conference News EuroPCR 2025 IVL Effective in Severely Calcified Lesions, Especially in Women Yael L. Maxwell May 22, 2025
Presentation EuroPCR 2025 The EMPOWER CAD study: women with calcified coronary arteries treated with intravascular lithotripsy Presenter: Margaret McEntegart May 22, 2025
News Conference News EuroPCR 2025 Early TAVI Improves Prognosis in Asymptomatic AS No Matter the Extent of Cardiac Damage Yael L. Maxwell May 21, 2025
News Conference News EuroPCR 2025 Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI Michael O'Riordan May 20, 2025
News Daily News Whether Angio or CT Come First in Evaluating Chest Pain, QoL After Is Similar Yael L. Maxwell May 20, 2025
News Conference News ESC Heart Failure 2025 AI-ECG Helps Find Subclinical Heart Failure in Kenya Todd Neale May 19, 2025
News Conference News European Congress on Obesity 2025 SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly Michael O'Riordan May 14, 2025
News Daily News Four-Dimensional Flow CMR Shows Promise in Aortic Stenosis Yael L. Maxwell May 13, 2025
News Daily News AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease Caitlin E. Cox May 06, 2025
News Daily News Lorundrostat Lowers BP in Treatment-Resistant Hypertension: Advance-HTN Yael L. Maxwell April 29, 2025
News Daily News TAVI and Complex/High-Risk PCI Safer if Staged, Registry Confirms Caitlin E. Cox April 28, 2025
News Daily News Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE Caitlin E. Cox April 23, 2025
News Daily News Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI Michael O'Riordan April 22, 2025
News Daily News High-Sensitivity Troponin Tests Might Aid in Primary Prevention Yael L. Maxwell April 16, 2025
News Daily News High BMI Before Pregnancy Tied to Greater CVD Risk Later in Life L.A. McKeown April 14, 2025
News Conference News ACC 2025 RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI Michael O'Riordan April 02, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
Presentation ACC 2025 Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial Presenter: Darren K. McGuire March 29, 2025